Prediction of response to therapy for autoimmune/inflammatory diseases using an activated macrophage-Targeted radioimaging agent

Molecular Pharmaceutics

Volumn 12, Issue 10, 2015, Pages 3547-3555

  Kelderhouse, Lindsay E ^a   Robins, Meridith T ^a   Rosenbalm, Katelyn E ^a   Hoylman, Emily K ^a   Mahalingam, Sakkarapalayam ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Activated macrophages; Atherosclerosis; EC20 radioimaging; Folate receptor targeting; Idiopathic pulmonary fibrosis; Inflammatory and autoimmune diseases; Rheumatoid arthritis; Ulcerative colitis

Indexed keywords

ABATACEPT; CIMETIDINE; DEXAMETHASONE; ETANERCEPT; ETARFOLATIDE TC 99M; FLUINDOSTATIN; METHOTREXATE; NAPROXEN; SALAZOSULFAPYRIDINE; VALSARTAN; ANTIINFLAMMATORY AGENT; FOLATE RECEPTOR; IMMUNOLOGIC FACTOR; TECHNETIUM 99M EC20 FOLATE PEPTIDE; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; LUNG FIBROSIS; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOGRAPHY; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANIMAL; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; BAGG ALBINO MOUSE; C57BL MOUSE; COLITIS, ULCERATIVE; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; MACROPHAGE; PULMONARY FIBROSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; FOLATE RECEPTORS, GPI-ANCHORED; IMMUNOLOGIC FACTORS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; ORGANOTECHNETIUM COMPOUNDS; PULMONARY FIBROSIS; TREATMENT OUTCOME;

EID: 84986579088     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00134     Document Type: Article

References (81)

1. Kuek, A.; Hazleman, B. L.; Ostor, A. J. K. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad. Med. J. 2007, 83, 251-260.
2. Lloyd, S.; Bujkiewicz, S.; Wailoo, A. J.; Sutton, A. J.; Scott, D. The effectiveness of anti-TNF-Alpha therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-Analysis. Rheumatology 2010, 49, 2313-2321.
3. Yazici, Y. Monitoring response to treatment in rheumatoid arthritis. Which tool is best suited for routine "Real World" Care? Bull. NYU Hosp Jt Dis. 2007, 65, S25-28.
4. Ory, P. A. Interpreting radiographic data in rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62, 597-604.
5. Taylor, P. C. The value of sensitive imaging modalities in rheumatoid arthritis. Arthritis Research & Therapy 2003, 5, 210-213.
6. Smolen, J. S.; Landewe, R. L.; Breedveld, F. C.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014, 73, 492-509.
7. Breedveld, F. C. Should rheumatoid arthritis be treated conservatively or aggressively? Rheumatology 2003, 42, ii41-ii43.
8. Quinn, M. A.; Emery, P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003, 21, S154-7.
9. Kevans, D.; Van Assche, G. Is there a therapeutic window of opportunity in early inflammatory bowel disease? Early stage inflammatory bowel disease: The actual management. Minerva Gastroenterol Dietol. 2013, 59, 299-312.
10. Lard, L. R.; Visser, H.; Speyer, I.; vander Horst-Bruinsma, I. E.; Zwinderman, A. H.; Breedveld, F. C.; Hazes, J. M. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 2001, 111, 446-451.
11. Tsakonas, E.; Fitzgerald, A. A.; Fitzcharle, M. A.; et al. Consequences of delayed therapy with second line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J. Rheumatol. 2000, 27, 623-629.
12. Boers, M.; Verhoeven, A. C.; Markusse, H. M.; van de Laar, M. A.; Westhovens, R.; van Denderen, J. C.; van Zeben, D.; Dijkmans, B. A.; Peeters, A. J.; Jacobs, P.; van den Brink, H. R.; Schouten, H. J.; van der Heijde, D. M.; Boonen, A.; van der Linden, S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350, 309-18.
13. Goekoop-Ruiterman, Y. P.; de Vries-Bouwstra, J. K.; Allaart, C. F.; van Zeben, D.; Kerstens, P. J.; Hazes, J. M.; Zwinderman, A. H.; Ronday, H. K.; Han, K. H.; Westedt, M. L.; Gerards, A. H.; van Groenendael, J. H.; Lems, W. F.; van Krugten, M. V.; Breedveld, F. C.; Dijkmans, B. A. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2008, 58, S126-35.
14. Lard, L. R.; Visser, H.; Speyer, I.; vander Horst-Bruinsma, I. E.; Zwinderman, A. H.; Breedveld, F. C.; Hazes, J. M. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 2001, 111, 446-51.
15. Nell, V. P.; Machold, K. P.; Eberl, G.; Stamm, T. A.; Uffmann, M.; Smolen, J. S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43, 906-14.
16. Lakatos, P. L.; Golovics, P. A.; David, G.; Pandur, T.; Erdelyi, Z.; Horvath, A.; Mester, G.; Balogh, M.; Szipocs, I.; Molnar, C.; Komaromi, E.; Veres, G.; Lovasz, B. D.; Szathmari, M.; Kiss, L. S.; Lakatos, L. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am. J. Gastroenterol. 2012, 107, 579-88.
17. Ramadas, A. V.; Gunesh, S.; Thomas, G. A.; Williams, G. T.; Hawthorne, A. B. Natural history of Crohn's disease in a populationbased cohort from Cardiff (1986-2003): A study of changes in medical treatment and surgical resection rates. Gut 2010, 59, 1200-6.
18. Rau, R. Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin. Rheumatol. 2005, 24, 189-202.
19. Kinne, R. W.; Bräuer, R.; Stuhlmüller, B.; Palombo-Kinne, E.; Burmester, G. Macrophages in rheumatoid arthritis. Arthritis Res. 2000, 2, 189-202.
20. Szekanecz, Z.; Koch, A. E. Vascular involvement in rheumatic diseases: "vascular rheumatology. Arthritis Res. Ther. 2008, 10, 224.
21. Clark, R. A.; Kupper, T. S. Misbehaving macrophages in the pathogensis of psoriasis. J. Clin. Invest. 2006, 116, 2084-2087.
22. Li, L.; Okusa, M. D. Macrophages, dendritic cells and kidney ischemia-reperfusion injury. Semin. Nephrol. 2010, 30, 268-277.
23. Bitterman, P. B.; Adelberg, S.; Crystal, R. G. Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophagederived growth factor in the interstitial lung disorders. J. Clin. Invest. 1983, 72, 1801-1813.
24. Wyburn, K. R.; Jose, M. D.; Wu, H.; Atkins, R. C.; Chadban, S. J. The role of macrophages in allograft rejection. Transplantation 2005, 80, 1641-1647.
25. Carlsen, H. S.; Baekkevold, E. S.; Morton, H. C.; Haraldsen, G.; Brandtzaeg, P. Monocyte-like and mature macrophages produce CXCL13 (B cell-Attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104, 3021-3027.
26. Carlson, S. L.; Parrish, M. E.; Springer, J. E.; Doty, K.; Dossett, L. Acute Inflammatory Response in Spinal Cord Following Impact Injury. Exp. Neurol. 1998, 151, 77-88.
27. Bruck, W.; Sommermeier, N.; Bergmann, M.; Zettl, U.; Goebel, H. H.; Kretzschmar, H. A.; Lassmann, H. Macrophages in multiple sclerosis. Immunobiology 1996, 195, 588-600.
28. Ishikawa, O.; Ishikawa, H. Macrophage infiltration in the skin of patients with systemic sclerosis. J. Rheumatol. 1992, 19, 1202-1206.
29. Demetter, P.; De Vos, M.; Van Huysse, J. A. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann. Rheum. Dis. 2005, 64, 321-324.
30. Manoussakis, M. N.; Boiu, S.; Korkolopoulou, P.; Kapsogeorgou, E. K.; Kavantzas, N.; Ziakas, P.; Patsouris, E.; Moutsopoulos, H. M. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum. 2007, 56, 3977-3988.
31. Atkins, R. C.; Glasgow, E. F.; Holdsworth, S. R.; Matthews, F. E. The macrophage in human rapidly progressive glomerulonephritis. Lancet 1976, 307, 830-832.
32. du Bois, R. M. The alveolar macrophage in sarcoidosis. Sarcoidosis. 1990, 7, 15-18.
33. Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P. Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum Dis. 2005, 64, 834-8.
34. Smeets, T. J.; Kraan, M. C.; van Loon, M. E.; Tak, P. P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003, 48, 2155-62.
35. Yanni, G.; Nabil, M.; Farahat, M. R.; Poston, R. N.; Panayi, G. S. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann. Rheum. Dis. 1994, 53, 315-22.
36. Pettit, A. R.; Weedon, H.; Ahern, M.; Zehntner, S.; Frazer, I. H.; Slavotinek, J.; Au, V.; Smith, M. D.; Thomas, R. Association of clinical, radiological and synovial immunopathological responses to antirheumatic treatment in rheumatoid arthritis. Rheumatology (Oxford) 2001, 40, 1243-55.
37. Dolhain, R. J.; Tak, P. P.; Dijkmans, B. A.; De Kuiper, P.; Breedveld, F. C.; Miltenburg, A. M. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Rheumatology 1998, 37, 502-8.
38. Smith, M. D.; Kraan, M. C.; Slavotinek, J.; Au, V.; Weedon, H.; Parker, A.; Coleman, M.; Roberts-Thomson, P. J.; Ahern, M. J. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) 2001, 40, 367-74.
39. Taylor, P. C.; Peters, A. M.; Paleolog, E.; Chapman, P. T.; Elliott, M. J.; McCloskey, R.; Feldmann, M.; Maini, R. N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43, 38-47.
40. Cunnane, G.; Madigan, A.; Murphy, E.; FitzGerald, O.; Bresnihan, B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001, 40, 62-9.
41. Nakashima-Matsushita, N.; Homma, T.; Yu, S.; et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42, 1609-1616.
42. Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.; Cheng, J. X.; Low, P. S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113, 438-446.
43. Paulos, C. M.; Varghese, B.; Widmer, W. R.; Breur, G. J.; Vlashi, E.; Low, P. S. Folate-Targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Research & Therapy. 2006, 8, R77.
44. Vaitilingam, B.; Chelvam, V.; Kularatne, S. A.; Poh, S.; Ayala- Lopez, W.; Low, P. S. A folate receptor-α-specific ligand that targets cancer tissue and not sites of inflammation. J. Nucl. Med. 2012, 53, 1127-1134.
45. Jager, N. A.; Westra, J.; van Dam, G. M.; Teteloshvili, N.; Tio, R. A.; Breek, J. C.; Slart, R. H.; Boersma, H.; Low, P. S.; Bijl, M.; Zeebregts, C. J. Targeted folate receptor β fluorescence imaging as a measure of inflammation to estimate vulnerability within human atherosclerotic carotid plaque. J. Nucl. Med. 2012, 53, 1222-1229.
46. Matteson, E. L.; Lowe, V. J.; Prendergast, F. G.; et al. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol. 2009, 27, 253-259.
47. Hansen, M. J.; Low, P. S. Folate Receptor Positive Macrophages: Cellular Targets for Imaging and Therapy of Inflammatory and Autoimmune Diseases. In Targeted Drug Strategies for Cancer and Inflammation; Jackman, A. L., Leamon, C. L., Eds.; Springer: New York; 2011; pp 181-193.
48. Brand, D. D.; Latham, K. A.; Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2007, 2, 1269-1275.
49. Leamon, C. P.; Reddy, J. A.; Dorton, R.; Bloomfield, A.; Emsweller, K.; Parker, N.; Westrick, E. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. J. Pharmacol. Exp. Ther. 2008, 327, 918-25.
50. Neurath, M. F.; Hildner, K.; Becker, C.; et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): A mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 1999, 115, 42-55.
51. Inglis, J. J.; Criado, G.; Medghalchi, M.; et al. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained Tcell response to type II collagen. Arthritis Research & Therapy. 2007, 9, R113.
52. Williams, R. O.; Feldmann, M.; Maini, R. N. Anti-Tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 9784-9788.
53. Webb, L. M.; Walmsley, M. J.; Feldmann, M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 1996, 26, 2320-2328.
54. Phadke, K.; Fouts, R. L.; Parrish, J. E.; Butler, L. D. Evaluation of the effects of various antiarthritic drugs on Type II collagen-induced mouse arthritic model. Immunopharmacology 1985, 10, 51-60.
55. Wirtz, S.; Neufert, C.; Weigmann, B.; Neurath, M. F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2, 541-546.
56. Smith, J. A. The effect of atropine, cimetidine and FPL 52694 on duodenal ulcers in mice. Eur. J. Pharmacol. 1983, 88, 215-221.
57. Axelsson, L. G.; Landstrom, E.; Bylund-Fellenius, A. C. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment. Pharmacol. Ther. 1998, 12, 925-934.
58. Zadelaar, S.; Kleemann, R.; Verschuren, L.; et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler., Thromb., Vasc. Biol. 2007, 27, 1706-1721.
59. Li, Z.; Iwai, M.; Wu, L.; Liu, H. W.; Chen, R.; Jinno, T.; Suzuki, J.; Tsuda, M.; Gao, X. Y.; Okumura, M.; Cui, T. X.; Horiuchi, M. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004, 44, 758-763.
60. Sata, M.; Nishimatsu, H.; Osuga, J.; Tanaka, K.; Ishizaka, N.; Ishibashi, S.; Hirata, Y.; Nagai, R. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004, 43, 1214-1220.
61. Moore, B. B.; Hogaboam, C. M. Murine models of pulmonary fibrosis. Am. J. Physiol Lung Cell Mol. Physiol. 2008, 294, L152-160.
62. Moeller, A.; Ask, K.; Warburton, D.; Gauldie, J.; Kolb, M. The bleomycin animal model; a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 2008, 40, 362-382.
63. Leamon, C. P.; Parker, M. A.; Vlahov, I. R.; et al. Synthesis and biological evaluation of EC20: A new folate-derived, 99mTc-based radiopharmaceutical. Bioconjugate Chem. 2002, 13, 1200-1210.
64. Reddy, J. A.; Xu, L. C.; Parker, N.; Vetzel, M.; Leamon, C. P. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptorpositive tumors. J. Nucl. Med. 2004, 45, 857-66.
65. Meir, K. S.; Leitersdorf, E. Atherosclerosis in the apolipoprotein E-deficient mouse: A decade of progress. Arterioscler., Thromb., Vasc. Biol. 2004, 24, 1006-1014.
66. Hunter, M. M.; Wang, A.; Parhar, K. S.; et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 2010, 138, 1395-1405.
67. Pechkovsky, D. V.; Prasse, A.; Kollert, F.; et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 2010, 137, 89-101.
68. Cañete, J. D.; Celis, R.; Hernández, V.; Pablos, J. L.; Sanmartí, R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann. Rheum. Dis. 2010, 69, 935-936.
69. Li, J.; Hirose, N.; Kawamura, M.; Arai, Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999, 143, 315-326.
70. Baetta, R.; Camera, M.; Comparato, C.; Altana, C.; Ezekowitz, M. D.; Tremoli, E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler., Thromb., Vasc. Biol. 2002, 22, 692-698.
71. Catrina, A. I.; Trollmo, C.; af Klint, E.; et al. Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum. 2005, 52, 61-72.
72. Chen, F.; Gong, L.; Zhang, L.; Wang, H.; Qi, X.; Wu, X.; Xiao, Y.; Cai, Y.; Liu, L.; Li, X.; Ren, J. Short courses of low dose dexamethasone delay bleomycin-induced lung fibrosis in rats. Eur. J. Pharmacol. 2006, 536, 287-295.
73. Nielsen, O. H.; Verspaget, H. W.; Elmgreen, J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-Aminosalicylic acid. Aliment. Pharmacol. Ther. 1988, 2, 203-211.
74. Zdolsek, J.; Eaton, J. W.; Tang, L. Histamine release and fibrinogen adsorption mediate acute inflammatory responses in biomaterial implants in humans. J. Transl. Med. 2007, 5, 31.
75. Kraan, M. C.; Reece, R. J.; Barg, E. C.; et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000, 43, 1820-1830.
76. Beecher, H. K. The powerful placebo. JAMA 1955, 159, 1602- 1604.
77. Langley, G. B.; Sheppeard, H.; Wigley, R. D. Placebo therapy in rheumatoid arthritis. Clin Exp Rheumatol. 1983, 1, 1721.
78. Williams, H. J.; Ward, J. R.; Dahl, S. L. A Controlled trail comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum. 1988, 31, 702-713.
79. Kularatne, S. A.; Bélanger, M.; Meng, X.; et al. Comparative analysis of folate derived PET imaging agents with [18F]-2-fluoro-2- deoxy-D-glucose using a rodent inflammatory paw model. Mol. Pharmaceutics 2013, 10, 3103-3111.
80. Kelderhouse, L. E.; Chelvam, V.; Wayua, C.; et al. Development of tumor-Targeted near infrared probes for fluorescence guided surgery. Bioconjugate Chem. 2013, 24, 1075-1080.
81. Chen, W. T.; Mahmood, U.; Weissleder, R.; Tung, C. H. Arthritis imaging using a near-infrared fluorescence folate-Targeted probe. Arthritis Res. Ther. 2005, 7, R310-R317.